KRAS mutation inhibitor

Phase 2

ZZhejiang University

KRAS mutation inhibitor is one of 3 therapeutic programs targeting Bile Duct Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Bile Duct CarcinomaNot yet recruiting

Bile Duct CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Bile Duct Carcinoma

#DrugCompanyPhaseTrials

Immune Checkpoint Inhibitors

PPeking Union Medical College Hospital

Phase 2

1 2

FGFR Inhibitor

UUniversity Health Network, Toronto

Phase 2

1 3

KRAS mutation inhibitor

ZZhejiang University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Not yet recruiting

Bile Duct Carcinoma

NCT07729917

Clinical

Trials by Indication[1]

Bile Duct Carcinoma1 trial

Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study

Not yet recruiting·ZZhejiang University·Phase 2·NCT07729917·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KRAS mutation inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for KRAS mutation inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: ZZhejiang University

KRAS mutation inhibitor

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Bile Duct Carcinoma1 trial

References

Drug Info

Quick Facts

Related News